RoslinCT

Happy New Year from all of us at RoslinCT!

Looking Back at 12 Days of Cell Therapy! Our 12 Days of Cell Therapy campaign highlighted the innovations, challenges, and breakthroughs shaping the future of cell therapy. Missed the campaign during the busy holiday season? No problem! We’ve pulled everything together in this video so you can catch up in one place. Flip through the slides below and let us know—what’s your biggest takeaway for the year ahead?

🎄 Over the past 2 weeks, we've highlighted standout achievements across the cell and gene therapy industry during our "12 Days of Cell Therapy" campaign. Today, on the 12th and final day, we turn the spotlight inward to celebrate the incredible achievements of our very own RoslinCT team. From advancing our services to supporting our partners in delivering life-changing therapies, this year has been filled with milestones we’re proud of. Thank you to our incredible team and everyone who has been part of this journey. Here’s to continuing to make a difference in cell therapy—together! Watch our highlights and celebrate the year with us! Happy Holidays from all of us at RoslinCT!

12 Days of Cell Therapy 🎄 On the final days of our countdown, we look ahead to the exciting opportunities the Cell and Gene Therapy sector holds as we close out 2024. Day 11: As the year draws to a close, we’ve witnessed ten regulatory approvals to date, including CASGEVY®, AMTAGVI, LENMELDY, BEQVEZ™, TECELRA, Upstaza™, AUCATZYL®, REGENECYTE™, SYMVESS™ and most recently, Ryoncil®. With additional therapies awaiting regulatory clearance, additional approvals could occur before year end. This promising wave of approvals highlights the growing confidence in the field, marking a key moment in the expansion of life-changing therapies for patients. With more therapies making their way through the regulatory process, the potential for transformative healthcare solutions continues to grow. Source: https://lnkd.in/e_SRS38z

12 Days of Cell Therapy 🎄 As we continue our celebration of the advancements in the Cell and Gene Therapy sector, we reflect on how far the field has come and the milestones that set the stage for the future of healthcare. Day 10: 2024 has also seen significant M&A activity, with major deals highlighting the growing interest in cell therapy. Novo Holdings acquired Catalent for $16.5 billion, Novartis acquired Kate Therapeutics for $1.1 billion, and Roche made a strategic investment in Poseida Therapeutics. These high-value acquisitions reflect the increasing recognition of cell therapies as essential to the next generation of treatments.   Are there any other noteworthy deals that caught your attention this year? Share them with us in the comments below!   Sources: https://lnkd.in/efNnymMS, https://lnkd.in/ePRRUx3q, https://lnkd.in/gvbwFU7r, https://lnkd.in/eD57gbzQ.

We're #hiring a new QCTS Scientist in Hopkinton, Massachusetts. Apply today or share this post with your network.

12 Days of Cell Therapy 🎄 With just 6 calendar days left until Christmas, we’re taking a moment to celebrate the incredible progress made in the Cell and Gene Therapy sector throughout 2024. Day 9: Since the first ground-breaking iPSC trial in 2008, the field has made extraordinary strides, with over 155 trials conducted to date. This progress reflects the growing confidence in iPSCs as a powerful tool in regenerative medicine, bringing us closer to new treatments for a wide range of diseases.   Source: https://lnkd.in/exJXWkB, https://lnkd.in/eHrTxTX3 Fig 4

At RoslinCT, we believe in making a difference both in and out of the lab. This season, we partnered with the Hopkinton non-profit, Project Just Because, Inc, to spread joy and support families in need. Through their Wishing Hearts initiative, we had the chance to fulfil holiday wishes for children and families in our community. Our incredible RoslinCT team stepped up with enthusiasm and generosity to make this festive season brighter for those who need it most. We’re honoured to be part of such a meaningful cause and to share the holiday spirit with our neighbours.

12 Days of Cell Therapy 🎄 The Cell and Gene Therapy sector continues to make remarkable progress, with ground-breaking developments shaping the future of healthcare. On Day 6, we highlighted that there are over 1,900 active Cell and Gene Therapy clinical trials worldwide—a testament to the sector’s rapid advancement. Day 8: Focusing on cell therapies alone, there are currently over 1,300 global cell therapy trials underway, addressing a broad range of indications, including oncology, autoimmune diseases, rare diseases, and neurology. This surge in trial activity highlights the increasing versatility and potential of cell therapies to transform the treatment landscape across multiple therapeutic areas. Source: https://lnkd.in/e9K5icWx

12 Days of Cell Therapy 🎄 With just 8 calendar days to go until Christmas, we continue our countdown of significant milestones in the Cell and Gene Therapy sector. Day 7: In 2024, the FDA granted approvals for several ground-breaking therapies across a range of conditions, marking a major step forward in cell therapy innovation. Notable approvals include Adaptimmune's TECELRA, the first T-cell receptor (TCR) therapy for synovial sarcoma, Autolus Therapeutics' AUCATZYL T cell immunotherapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and Iovance Biotherapeutics, Inc.’s first tumor-infiltrating lymphocyte (TIL) therapy, AMTAGVI, for advanced melanoma. These advances highlight the expanding role of cell therapies in treating cancers and genetic disorders, providing new, life-changing options for patients with previously limited choices. Sources: FDA, Adaptimmune, Autolus, Iovance https://lnkd.in/etxeMZUK https://lnkd.in/gp68yd6U https://lnkd.in/gm2DMrnc